Last reviewed · How we verify
SARS-CoV-2 Virus 1x10^1 TCID50 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
SARS-CoV-2 Virus 1x10^1 TCID50 (SARS-CoV-2 Virus 1x10^1 TCID50) — Imperial College London.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SARS-CoV-2 Virus 1x10^1 TCID50 TARGET | SARS-CoV-2 Virus 1x10^1 TCID50 | Imperial College London | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SARS-CoV-2 Virus 1x10^1 TCID50 CI watch — RSS
- SARS-CoV-2 Virus 1x10^1 TCID50 CI watch — Atom
- SARS-CoV-2 Virus 1x10^1 TCID50 CI watch — JSON
- SARS-CoV-2 Virus 1x10^1 TCID50 alone — RSS
Cite this brief
Drug Landscape (2026). SARS-CoV-2 Virus 1x10^1 TCID50 — Competitive Intelligence Brief. https://druglandscape.com/ci/sars-cov-2-virus-1x10-1-tcid50. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab